Xiaomei Ren

4.8k total citations
127 papers, 3.8k citations indexed

About

Xiaomei Ren is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Xiaomei Ren has authored 127 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Molecular Biology, 29 papers in Oncology and 20 papers in Organic Chemistry. Recurrent topics in Xiaomei Ren's work include HER2/EGFR in Cancer Research (14 papers), Lung Cancer Treatments and Mutations (13 papers) and Cancer therapeutics and mechanisms (12 papers). Xiaomei Ren is often cited by papers focused on HER2/EGFR in Cancer Research (14 papers), Lung Cancer Treatments and Mutations (13 papers) and Cancer therapeutics and mechanisms (12 papers). Xiaomei Ren collaborates with scholars based in China, United States and Thailand. Xiaomei Ren's co-authors include Ke Ding, Zhang Zhang, Xiaoyun Lu, Zhengchao Tu, Zhenghua Xiao, Gang Yang, Jinfeng Luo, Haiyan Long, Kunlong Ma and Wei Qin and has published in prestigious journals such as Journal of the American Chemical Society, Nucleic Acids Research and Angewandte Chemie International Edition.

In The Last Decade

Xiaomei Ren

122 papers receiving 3.7k citations

Peers

Countries citing papers authored by Xiaomei Ren

Since Specialization

Citations

This map shows the geographic impact of Xiaomei Ren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaomei Ren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaomei Ren more than expected).

Fields of papers citing papers by Xiaomei Ren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaomei Ren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaomei Ren. The network helps show where Xiaomei Ren may publish in the future.

Co-authorship network of co-authors of Xiaomei Ren

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaomei Ren. A scholar is included among the top collaborators of Xiaomei Ren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaomei Ren. Xiaomei Ren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The design and synthesis of selective and potent selenium-containing KRASG12D inhibitors 2025 ·European Journal of Medicinal Chemistry ·(unknown), Yayuan Yang, (unknown), Jie Wang, Ping Zhang, Yang Zhou, Jinwei Zhang, Xiaomei Ren, Zhen Wang, Weixue Huang, Zhimin Zhang, Xin Zhang, (unknown), Fengtao Zhou	0
2	Discovery of YJZ5118: A Potent and Highly Selective Irreversible CDK12/13 Inhibitor with Synergistic Effects in Combination with Akt Inhibition 2025 ·Journal of Medicinal Chemistry ·(unknown), Yu‐Sun Chang, (unknown), Weixue Huang, (unknown), (unknown), Wenyan Liu, Licheng Zhou, Yang Zhou, Xiaomei Ren, Rahul Mannan, Somnath Mahapatra, Yuping Zhang, (unknown), (unknown), Zhen Wang, (unknown), Arul M. Chinnaiyan, Ke Ding	0
3	O-Cyanobenzaldehydes Irreversibly Modify Both Buried and Exposed Lysine Residues in Live Cells 2025 ·Journal of the American Chemical Society ·(unknown), (unknown), Liping Duan, Weixue Huang, Jiangnan Zheng, Shijie Zhang, Xinling Li, (unknown), Yang Zhou, Nan Ma, Xiaomei Ren, Jinwei Zhang, Zhen Wang, Yujun Zhao, Ruijun Tian, Zhimin Zhang, Ke Ding	5
4	Discovery of LHF418 as a new potent SOS1 PROTAC degrader 2024 ·Bioorganic & Medicinal Chemistry ·Huifan Li, (unknown), Yihan Chen, Fengtao Zhou, Xiaomei Ren, (unknown), Jian Wang, Zhen Wang, Weixue Huang	4
5	Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader 2024 ·Journal of Medicinal Chemistry ·(unknown), Abhijit Parolia, Yihan Liu, (unknown), (unknown), Yuanyuan Qiao, Sanjana Eyunni, (unknown), Chungen Li, Yongxing Wang, Fengtao Zhou, Weixue Huang, Xiaomei Ren, Zhen Wang, Arul M. Chinnaiyan, Ke Ding	13
6	Discovery of 5-aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors 2024 ·European Journal of Medicinal Chemistry ·(unknown), Rong Liu, (unknown), (unknown), Xiaomei Ren, Fengtao Zhou, Jinwei Zhang, Weixue Huang, Zhen Wang, Ke Ding	5
7	Two new iridoids and one new flavonoid glucoside from the tender leaves of Eucommia ulmoides and their anti-inflammatory activity 2023 ·Phytochemistry Letters ·(unknown), Xiaomei Ren, Zhu‐Zhen Han, (unknown), Gui‐Xin Chou, Yingbo Yang, (unknown)	1
8	Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia 2023 ·European Journal of Medicinal Chemistry ·Wenyan Liu, Yu Bai, Licheng Zhou, Jian Jin, Meiying Zhang, Yongxing Wang, (unknown), Weixue Huang, Xiaomei Ren, Nan Ma, Fengtao Zhou, Zhen Wang, Ke Ding	13
9	Discovery of a First-in-Class Degrader for the Lipid Kinase PIKfyve 2023 ·Journal of Medicinal Chemistry ·Chungen Li, Yuanyuan Qiao, Xia Jiang, (unknown), Yang Zheng, (unknown), (unknown), Fengtao Zhou, Yang Zhou, Weixue Huang, Xiaomei Ren, Yuzhuo Wang, Zhen Wang, Arul M. Chinnaiyan, Ke Ding	10
10	Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors 2022 ·Journal of Medicinal Chemistry ·(unknown), Yunong Zhang, (unknown), (unknown), Peng Xia, Jian Zou, Licheng Zhou, Li Tan, (unknown), Yang Zhou, Hoon Hur, Jing Ai, Zhen Wang, Xiaomei Ren, Zhang Zhang, Ke Ding	15
11	Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations 2022 ·Journal of Medicinal Chemistry ·(unknown), Mengzhen Lai, Tao Zhang, Yuqing Chen, Linjiang Tong, Sujie Zhu, Yang Zhou, Xiaomei Ren, Jian Ding, Hua Xie, Xiaoyun Lu, Ke Ding	43
12	Discovery of Hexahydrofuro[3,2-b]furans as New Kinase-Selective and Orally Bioavailable JAK3 Inhibitors for the Treatment of Leukemia Harboring a JAK3 Activating Mutant 2022 ·Journal of Medicinal Chemistry ·(unknown), (unknown), Xiaojuan Song, Chong Lei, Xiaoqiang He, Jie Wang, Yiling Liu, Yang Zhou, Jian‐Guo Song, Lijie Peng, (unknown), (unknown), Xiaomei Ren, Zhengchao Tu, Zhengqiu Li, Zhen Wang, Zhang Zhang, Ke Ding	6
13	Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells 2022 ·Journal of Medicinal Chemistry ·Fang Xu, Xin Zhang, Zhipeng Chen, Sheng He, (unknown), (unknown), Yongjin Wang, (unknown), (unknown), (unknown), Jeff B. Smaill, Adam V. Patterson, Zhimin Zhang, Liang Chen, Xiaomei Ren, Ke Ding	28
14	Discovery of JND003 as a New Selective Estrogen-Related Receptor α Agonist Alleviating Nonalcoholic Fatty Liver Disease and Insulin Resistance 2022 ·PubMed ·Liufeng Mao, Lijie Peng, Xiaomei Ren, Yi Chu, Tao Nie, Wanhua Lin, Andrew E. Libby, Yong Xu, (unknown), Chong Lei, Kerry M. Loomes, Na Wang, Jinsong Liu, Moshe Levi, Donghai Wu, Xiaoyan Hui, Ke Ding	7
15	GZD824 overcomes FGFR1‐V561F/M mutant resistance in vitro and in vivo 2021 ·Cancer Medicine ·(unknown), (unknown), (unknown), (unknown), (unknown), Xiaojuan Song, Zhengchao Tu, Yuting Wang, Xiaomei Ren, Ke Ding, Zhang Zhang	17
16	Design, synthesis and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitors 2019 ·European Journal of Medicinal Chemistry ·(unknown), Yongjin Wang, Yuting Wang, (unknown), Xiaomei Ren, Lei Zhang, Yong Xu, Zhang Zhang, Zhimin Zhang, Xiaoyun Lu, Ke Ding	17
17	Identification of New Small-Molecule Inducers of Estrogen-related Receptor α (ERRα) Degradation 2019 ·ACS Medicinal Chemistry Letters ·Lijie Peng, Zhensheng Zhang, Chong Lei, (unknown), Zhang Zhang, Xiaomei Ren, (unknown), Yan Zhang, Yong Xu, Ke Ding	55
18	Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2-a]pyrazin-3-ylethynyl)-4-isopropyl-N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2 2018 ·Journal of Medicinal Chemistry ·Zhen Wang, Yali Zhang, Daniel M. Pinkas, (unknown), Jinfeng Luo, Huocong Huang, (unknown), Qiuping Xiang, Tingting Xu, (unknown), Dongsheng Zhu, Zhengchao Tu, Xiaomei Ren, Rolf A. Brekken, Alex N. Bullock, Guang Liang, Ke Ding, Xiaoyun Lu	29
19	Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma 2017 ·Molecular Cancer Therapeutics ·Kristina Y. Aguilera, Huocong Huang, Wenting Du, (unknown), Zhen Wang, Stefan Hinz, Tae Hyun Hwang, Huamin Wang, Jason B. Fleming, Diego H. Castrillón, Xiaomei Ren, Ke Ding, Rolf A. Brekken	88
20	Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors 2017 ·ACS Medicinal Chemistry Letters ·Zhen Wang, Yali Zhang, Sergio G. Bartual, Jinfeng Luo, Tingting Xu, Wenting Du, (unknown), Zhengchao Tu, Rolf A. Brekken, Xiaomei Ren, Alex N. Bullock, Guang Liang, Xiaoyun Lu, Ke Ding	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact